The US Food and Drug Administration has issued final guidance for prescription drug manufacturers clarifying how they may display the proprietary and established names of drug products in promotional materials, including advertisements disseminated via social media websites1,2...
Scrip Regulatory Affairs
US FDA guidance explains how to display proprietary and established drug names in promotional material
26 January 2012
Vibha Sharma
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Long-awaited EU medtech e-IFU regulation is published, application deferred for one year
- US FDA adopts proposals to improve public access to compliance, enforcement data
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
- "Vast" overhaul of EU pharmacovigilance may mean higher industry fees
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
